Reverie Labs, a Cambridge, Mass.-based pharmaceutical company pioneering the application of machine learning to developing next-generation small molecule kinase inhibitors, closed its $25M Series A financing.
In conjunction with the financing, which brings the total capital raised to more than $32M, Wayne Holman, M.D., founder and CEO of Ridgeback Capital, joined Reverie’s Board of Directors.
The company will use the proceeds to advance its internal and partnered drug discovery programs towards the clinic, further develop its innovative computational discovery platform, and grow its cross-disciplinary team of scientists and engineers.
Led by Jonah Kallenbach, co-founder and CEO, and Ankit Gupta, co-founder and CTO, Reverie is a pharmaceutical company leveraging machine learning, physics-based modeling, and massive-scale computational infrastructure to engineer new medicines. The technology consists of predictive tools, new methods for focused molecular generation, and a scalable cloud framework, which allows for the unhindered exploration of chemical space.
The company is advancing a lead program, which, rapidly advancing towards the clinic, is targeting a well-validated disease mechanism with highly specific and brain-penetrant kinase inhibitors. The company is also supplementing its pipeline through partnerships, including a multi-target strategic collaboration agreement with Roche and Genentech, a member of the Roche Group.